During the past decade, Lin Shen conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lin Shen" #1 collaborator was "Roche Pharma AG" with 1 trials as a collaborator and "Xiansheng Pharmaceutical Company" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Lin Shen" are "Advanced Gastric Cancer" (3 trials), "Gastric Adenocarcinoma" (1 trials) and "Gastric Cancer" (1 trials). Many other conditions were trialed in "Lin Shen" in a lesser frequency.

Most popular intervention types in "Lin Shen" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "capecitabine" (2 trials), "cisplatin" (2 trials), "Clinical chemo-drugs" (1 trials), "Nanoparticle Albumin-Bound Paclitaxel" (1 trials) and "Paclitaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Lin Shen" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Lin Shen". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Lin Shen, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Lin Shen, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".